Abstract

A systematic nomenclature for allergens originated in the early 1980s, when few protein allergens had been described. A group of scientists led by Dr. David G. Marsh developed a nomenclature based on the Linnaean taxonomy, and further established the World Health Organization/International Union of Immunological Societies (WHO/IUIS) Allergen Nomenclature Sub-Committee in 1986. Its stated aim was to standardize the names given to the antigens (allergens) that caused IgE-mediated allergies in humans. The Sub-Committee first published a revised list of allergen names in 1986, which continued to grow with rare publications until 1994. Between 1994 and 2007 the database was a text table online, then converted to a more readily updated website. The allergen list became the Allergen Nomenclature database (www.allergen.org), which currently includes approximately 880 proteins from a wide variety of sources. The Sub-Committee includes experts on clinical and molecular allergology. They review submissions of allergen candidates, using evidence-based criteria developed by the Sub-Committee. The review process assesses the biochemical analysis and the proof of allergenicity submitted, and aims to assign allergen names prior to publication. The Sub-Committee maintains and revises the database, and addresses continuous challenges as new “omics” technologies provide increasing data about potential new allergens. Most journals publishing information on new allergens require an official allergen name, which involves submission of confidential data to the WHO/IUIS Allergen Nomenclature Sub-Committee, sufficient to demonstrate binding of IgE from allergic subjects to the purified protein.

Highlights

  • Reports of adverse health problems that are thought to represent allergies and asthma date back more than 3000 years from Egypt, Rome and China, but these are not well documented

  • Since the antibody recognition is directed to the glycan structure rather than the protein structure, they are not included in the WHO/Immunological Society (IUIS) database as allergens unless Immunoglobulin E (IgE) binding has been demonstrated against the deglycosylated protein

  • The WHO/IUIS Allergen Nomenclature Sub-Committee serves as an expert professional group that reviews supporting evidence of allergenicity of proteins, assigns names and manages an official list of recognized allergens

Read more

Summary

Introduction

Reports of adverse health problems that are thought to represent allergies and asthma date back more than 3000 years from Egypt, Rome and China, but these are not well documented. Individual immunotherapeutic reagents and prescriptions may be available for improved therapy These developments further underpin the need for a consistent and unambiguous nomenclature of allergens. This process ensures that an appropriate, approved and non-redundant name is assigned to the allergen for any further publication. The benefit of this nomenclature system is that allergens are named in a properly documented, consistent and unambiguous manner, creating and maintaining clarity amongst the scientific, clinical and regulatory communities

Evolution of allergen names
Current allergen nomenclature conventions
Review process by the Allergen Nomenclature Sub-Committee
Essential criteria for acceptance of a protein as an allergen in the database
Analysis of candidate allergens by biochemistry and molecular biology
Proof of allergenicity of the newly identified proteins
Revision of allergen names
Difficulty in naming certain allergens
Cross-reactivity might impair the identification of source-specific allergens
Is the Sub-Committee naming too many allergens?
Integration of big data from ‘omics’ research
Assignment of names before publication
Other allergen sequence and structure databases
Future directions and new initiatives
10. Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call